Pediatrix Medical Group (NYSE:MD) Raised to “Buy” at StockNews.com

Pediatrix Medical Group (NYSE:MD) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a report released on Thursday.

Several other equities analysts have also recently commented on MD. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a report on Monday, November 4th. Truist Financial lowered their target price on Pediatrix Medical Group from $16.00 to $15.00 and set a “hold” rating on the stock in a research note on Monday. Macquarie assumed coverage on Pediatrix Medical Group in a research note on Monday, December 16th. They set an “outperform” rating and a $18.00 price target for the company. Mizuho boosted their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. Finally, Jefferies Financial Group raised their price objective on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Pediatrix Medical Group currently has a consensus rating of “Hold” and a consensus target price of $16.25.

Pediatrix Medical Group Stock Up 1.0 %

Shares of MD traded up $0.12 during mid-day trading on Thursday, reaching $12.73. The company’s stock had a trading volume of 342,371 shares, compared to its average volume of 432,674. The company has a market cap of $1.09 billion, a price-to-earnings ratio of -4.16, a price-to-earnings-growth ratio of 2.00 and a beta of 1.58. The business has a fifty day moving average of $14.35 and a 200 day moving average of $11.54. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. Pediatrix Medical Group has a 1 year low of $6.62 and a 1 year high of $16.41.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. During the same period in the prior year, the business earned $0.29 EPS. The business’s revenue for the quarter was up .9% on a year-over-year basis. As a group, analysts forecast that Pediatrix Medical Group will post 1.26 earnings per share for the current fiscal year.

Insider Activity at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Mark S. Ordan sold 27,600 shares of the business’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the transaction, the director now directly owns 138,683 shares in the company, valued at $2,128,784.05. The trade was a 16.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Mary Ann E. Moore sold 8,108 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the sale, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. The trade was a 5.63 % decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Pediatrix Medical Group

Institutional investors have recently modified their holdings of the stock. Nordea Investment Management AB increased its position in Pediatrix Medical Group by 51.6% in the fourth quarter. Nordea Investment Management AB now owns 263,633 shares of the company’s stock worth $3,504,000 after purchasing an additional 89,739 shares during the period. Everence Capital Management Inc. grew its position in shares of Pediatrix Medical Group by 7.5% during the 4th quarter. Everence Capital Management Inc. now owns 13,840 shares of the company’s stock worth $182,000 after buying an additional 960 shares during the period. Principal Financial Group Inc. raised its stake in shares of Pediatrix Medical Group by 14.1% during the third quarter. Principal Financial Group Inc. now owns 513,618 shares of the company’s stock worth $5,953,000 after buying an additional 63,581 shares during the last quarter. Franklin Resources Inc. bought a new stake in shares of Pediatrix Medical Group during the third quarter worth approximately $598,000. Finally, Barclays PLC boosted its stake in Pediatrix Medical Group by 302.9% in the third quarter. Barclays PLC now owns 142,087 shares of the company’s stock valued at $1,646,000 after acquiring an additional 106,817 shares during the last quarter. 97.71% of the stock is owned by institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.